Vaccines found Vaccines on trial Adults on trials Confirmed cases People vaccinated

0

141↑

23,706↑

9,561,229↑

0

Last updated:

COVID-19 Vaccine Development Stages

According to World Health Organization (WHO) development of a new vaccine falls into 5 stages:

Pre-clinical
Phase I
Phase II
Phase III
Licensing
Mass Production

A mix of legacy drug makers and small startups have stepped forward with plans to develop vaccines or treatments that target the infection caused by the novel coronavirus.


All Vaccine Candidates Pre-Clinical Phase I Phase II Phase III Licensing Mass Production

141↑

125

8↑

7↑

1

0

0

Development of a new vaccine falls into 5 stages:

1. Pre-clinical
2. Clinical development ( in three phases)
3. Regulatory review and approval
4. Manufacturing
5. Quality control

Once a promising vaccine is identified, it will firstly undergo scrupulous laboratory testing. This includes careful examination and testing of the vaccine and its ingredients. These tests evaluate the safety of the vaccine, and how well it prevents a disease.

If positive results are achieved in the lab, a manufacturer can then apply to do clinical trials. These trials typically involve several thousand healthy volunteers participants on a voluntary basis, whose safety is ensured by national regulatory authorities, and last for many years. The trials are bound by strict regulations and take place across three main phases:

During Phase I, small groups (approximately 20-50 people) receive the vaccine. This phase will assess the safety, side effects, appropriate dosage, method of administration and composition of the vaccine. If it is successful, it will proceed to Phase II. At this stage, the vaccine is usually given to several hundred people. This group will have the same characteristics (e.g. age, sex) as the people for whom the vaccine is intended to be given. In Phase III, the vaccine is usually given to thousands of people to help ensure it is safe and effective for broader use.

The results of all these studies will be assessed when regulators decide whether to approve a vaccine.

Studies may also take place after a vaccine is introduced. They enable scientists to monitor efficacy and safety among an even larger number of people, over a longer timeframe.

COVID-19 Vaccine Candidates in Clinical Evaluation

1. University of Oxford

Platform: Non-Replicating Viral vector
Group size: 10,260 adults and children
Country: England
Source link 1
Source link 2
Source link 3

Pre-clinical
Phase I
Phase II
Phase III

  • Group size: Up to 10,260 adults and children across the UK are enrolled
  • Pharmaceutical form: Solution for injection
  • Product name: ChAdOx1 nCoV-19
  • ChAdOx1 nCoV-19 is made from a virus (ChAdOx1), which is a weakened version of a common cold virus (adenovirus)
  • Ethics Committee Opinion of the trial application: Favorable


2. CanSino Biological Inc./Beijing Institute of Biotechnology

Platform: Non-Replicating Viral Vector
Group Size: 500 adults
Country: China
Source link

Pre-clinical
Phase I
Phase II

  • Group Size: 500 adults over 18 in Wuhan are enrolled
  • Pharmaceutical form: Solution for injection
  • Outcome: Anti-S antibody IgG titer on day 28 post vaccination
  • Ethics Committee Opinion of the trial application: N/A


3. Moderna/ NIAID

Platform: RNA
Group Size: 155 adults
Country: Massachusetts, United States
Source link

Pre-clinical
Phase I
Phase II

  • Group Size: 155 adults
  • Pharmaceutical form: Solution for injection
  • Requires multiple injections
  • Ethics Committee Opinion of the trial application: N/A
  • Product name:mRNA-1273


4. Wuhan Institute of Biological Products/Sinopharm

Platform: Inactivated vaccine
Group Size: 1,456 adults and children
Country: China
Source link

Pre-clinical
Phase I
Phase II

  • Group Size: 1,456 healthy subjects aged 6 years and above
  • Pharmaceutical form: Solution for injection
  • Outcome:1)Incidence of Serious Adverse Events, 2) Four-fold growth rate and antibody level (GMT, GMI) of serum antibody against COVID-19
  • Ethics Committee Opinion of the trial application: N/A
  • Product name:N/A


5. Wuhan Institute of Biological Products/Sinopharm

Platform: inactivated vaccine
Group Size: 2,004 adults and children
Country: China
Source link

Pre-clinical
Phase I
Phase II

  • Group Size: 2,004 healthy subjects aged 3 years and above
  • Pharmaceutical form: Solution for injection
  • Outcome:1)Incidence of Serious Adverse Events, 2) Four-fold growth rate and antibody level (GMT, GMI) of serum antibody against COVID-19
  • Ethics Committee Opinion of the trial application: N/A
  • Product name:N/A


6. Sinovac

Platform: inactivated vaccine
Group Size: 422 adults
Country: China
Source link

Pre-clinical
Phase I
Phase II

  • Group Size: 422 healthy adults aged 60 Years and older
  • Pharmaceutical form: Solution for injection, two doses
  • Outcome:Neutralizing antibody assay will be performed using the micro-neutralization method.
  • Ethics Committee Opinion of the trial application: N/A
  • Product name:N/A


7. Novavax

Platform: Protein Subunit
Group Size: 131 adults
Country: Maryland, United States
Source link

Pre-clinical
Phase I
Phase II

  • Group Size: 131 healthy adults
  • Pharmaceutical form: Solution for injection, two doses
  • Outcome:N/A
  • Ethics Committee Opinion of the trial application: N/A
  • Product name:N/A


8. BioNTech/Fosun Pharma/Pfizer

Platform: 3 LNP-mRNAs
Group Size: 7,796 adults
Country: Germany, China, New York-United States
Source link

Pre-clinical
Phase I
Phase II

  • Group Size: 196 adults in Germany and 7600 adults in USA
  • Pharmaceutical form: Solution for injection
  • Outcome:Functional antibody responses after the primary immunization.
  • Ethics Committee Opinion of the trial application: Favorable
  • Product name:N/A


9. Institute of Medical Biology, Chinese Academy of Medical Sciences

Platform: Inactivated vaccine
Group Size: N/A
Country: China
Source link

Pre-clinical
Phase I

  • Group Size: 942 participants
  • Pharmaceutical form: N/A
  • Outcome:Seroconversion rate of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,28
  • Ethics Committee Opinion of the trial application: N/A
  • Product name:N/A


10. Inovio Pharmaceuticals

Platform: DNA plasmid vaccine with electroporation
Group Size: 40 adults
Country: Pennsylvania, United States
Source link

Pre-clinical
Phase I

  • Group Size: 40 healthy adults (18-50 years)
  • Pharmaceutical form: Solution for injection
  • Outcome:N/A
  • Ethics Committee Opinion of the trial application: N/A
  • Product name:N/A

11. Imperial College London

Platform: RNA
Group Size: 320
Country: UK
Source link

Pre-clinical
Phase I

  • Group Size: N/A
  • Pharmaceutical form: N/A
  • Outcome:N/A
  • Ethics Committee Opinion of the trial application: N/A
  • Product name:N/A

(new) 12. Genexine Consortium

Platform: DNA
Group Size: 190 participants
Country: South Korea
Source link

Pre-clinical
Phase I

  • Group Size: 190 participants 18 to 50 years
  • Pharmaceutical form: N/A
  • Outcome:N/A
  • Ethics Committee Opinion of the trial application: N/A
  • Product name:N/A

(new) 13. Gamaleya Research Institute

Platform: Non-Replicating Viral Vector
Group Size: 38 participants
Country: Russia
Source link

Pre-clinical
Phase I

  • Group Size: 38 participants 18 to 60 years
  • Pharmaceutical form: N/A
  • Outcome:N/A
  • Ethics Committee Opinion of the trial application: N/A
  • Product name:N/A

(new) 14. Clover Biopharmaceuticals Inc./GSK/Dynavax

Platform: Protein Subunit
Group Size: 150 participants
Country: Australia
Source link

Pre-clinical
Phase I

  • Group Size: 150 participants 18 to 60 years
  • Pharmaceutical form: N/A
  • Outcome:N/A
  • Ethics Committee Opinion of the trial application: N/A
  • Product name:SCB-2019 as COVID-19 Vaccine

(new) 15. Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology,Chinese Academy of Sciences

Platform: Protein Subunit
Group Size: N/A
Country: China
Source link

Pre-clinical
Phase I

  • Group Size: N/As
  • Pharmaceutical form: N/A
  • Outcome:N/A
  • Ethics Committee Opinion of the trial application: N/A
  • Product name:N/A

(new) 16. Curevac

Platform: RNA
Group Size: N/A
Country: Germany
Source link

Pre-clinical
Phase I

  • Group Size: N/As
  • Pharmaceutical form: N/A
  • Outcome:N/A
  • Ethics Committee Opinion of the trial application: N/A
  • Product name:N/A


See all 139 trials

Newly Added


(new) 12. Genexine Consortium

Pre-clinical
Phase I

(new) 13. Gamaleya Research Institute

Pre-clinical
Phase I

(new) 14. Clover Biopharmaceuticals Inc./GSK/Dynavax

Pre-clinical
Phase I

(new) 15. Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology,Chinese Academy of Sciences

Pre-clinical
Phase I

(new) 16. Curevac

Pre-clinical
Phase I

(new)124. Israel Institute for Biological Research/Weizmann Institute of Science

Pre-clinical

(new)125. IrsiCaixa AIDS Research/ IRTACReSA/ Barcelona Supercomputing Centre/ Grifols

Pre-clinical

See all 139 trials

Charts and Graphs


COVID-19 Vaccine Candidates

Vaccine Types

Number of Vaccine Trials per Country

Vaccine Trials per Country

People on Trials per Project

COVID-19 Vaccine Candidates

Vaccine Types

Number of Vaccine Trials per Country

Vaccine Trials per Country

People on Trials per Project

Number of People on Trials


DISCLAIMER:

These information are acquired from the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global pandemic of the novel coronavirus (SARS-CoV-2).

Home All candidates Sources About Vacine types

Contact:

E-mail: [email protected]